LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • November 9th, 2011 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Delaware
Plaintiff Medicis Pharmaceutical Corporation (“Medicis”) and Defendants Lupin Limited & Lupin Pharmaceuticals Inc. (collectively “Defendants”) having met, conferred, and agreed to resolve their dispute upon execution of a separate Settlement Agreement (“Settlement Agreement”), Medicis respectfully moves for entry of the executed Consent Judgment and Permanent Injunction submitted herewith. Defendants do not oppose this motion.
LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • November 9th, 2010 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Delaware
THIS LICENSE AND SETTLEMENT AGREEMENT (this “Agreement”) dated as of September 21, 2010 (the "Effective Date”) is entered into between Medicis Pharmaceutical Corporation, a Delaware corporation with an address at 7720 North Dobson Road, Scottsdale, Arizona 85256 (together with its Affiliates, collectively, “Medicis”), and Taro Pharmaceutical Industries Ltd., an Israeli corporation with an address at Euro Park (Italy Building), Yakum Business Park, Yakum 60972, Israel and Taro Pharmaceuticals U.S.A., Inc., a New York Corporation with an address of Three Skyline Drive, Hawthorne, NY 10532, USA (together with their Affiliates, collectively, “Taro”).
SECOND AMENDMENT TO LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • August 6th, 2021 • Dermata Therapeutics, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO LICENSE AND SETTLEMENT AGREEMENT (“Second Amendment”) is made, effective as of the date executed below by both parties, by and between Villani, Inc., a Delaware corporation with mailing address of 220 Newport Center Dr., Suite 11-578, Newport Beach CA 92660 (the “Licensor”) and Dermata Therapeutics, Inc., a Delaware corporation as successor to Dermata Therapeutics, LLC a Delaware limited liability company having a principal place of business at 3525 Del Mar Heights Rd., #322, San Diego, California 92130 (“Dermata”), and Maria Villani exclusively for purposes of the Mutual Release and Settlement herein. Licensor and Dermata may each be referred to herein individual as a “Party” and collectively as the “Parties.” All defined terms in the License Agreement (as amended above) shall have the same meanings in this Second Amendment.
LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • May 10th, 2012 • Conceptus Inc • Surgical & medical instruments & apparatus • California
Hologic, Inc. (“Hologic”) and Conceptus, Inc. (“Conceptus”), by their attorneys, respectfully move the Court to reopen this case to enter a stipulated dismissal of Hologic’s claims against Conceptus.
LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • November 9th, 2011 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Delaware
Plaintiff Medicis Pharmaceutical Corporation (“Medicis”) and Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. (collectively “Defendants”) having met, conferred, and agreed to resolve their dispute upon execution of a separate License and Settlement Agreement (“Settlement Agreement”), Medicis respectfully moves for entry of the executed Consent Judgment and Permanent Injunction submitted herewith. Defendants do not oppose this motion.
LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • March 1st, 2010 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Arizona
This matter is before the Court on the unopposed motion of Plaintiff Medicis Pharmaceutical Corporation (“Medicis”) and Defendants Glenmark Generics Inc., USA and Glenmark Generics Ltd. (collectively, “Glenmark”).
LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • August 9th, 2010 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Delaware
This matter is before the Court on the unopposed motion of Plaintiff Medicis Pharmaceutical Corporation (“Medicis”) and Defendants Ranbaxy Inc. and Ranbaxy Laboratories Ltd. (collectively referred to herein as “Ranbaxy”).
AMENDMENT NO. 1 TO LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • May 8th, 2012 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Delaware
THIS AMENDMENT NO. 1 TO LICENSE AND SETTLEMENT AGREEMENT (this “Amendment”) dated as of February 29, 2012 (the “Amendment Date”), is entered into between Medicis Pharmaceutical Corporation, a Delaware corporation with an address at 7720 North Dobson Road, Scottsdale, Arizona 85256 on behalf of itself and its Affiliates (collectively, “Medicis”), and Ranbaxy Inc., a Delaware corporation with an address at 600 College Road East, Princeton, New Jersey 08540 and Ranbaxy Laboratories Limited, a corporation organized under the laws of the Republic of India with an address at Plot 90, Sector 32, Gurgaon (Haryana) India - 122001, on behalf of themselves and their respective Affiliates (collectively, “Ranbaxy”).
LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • March 2nd, 2009 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Arizona
a pharmaceutically suitable delivery vehicle having an intragranular fast dissolving carrier, an extragranular fast dissolving carrier, and a slow dissolving carrier, wherein said minocycline, said intragranular fast dissolving carrier and said slow dissolving carrier form granules of slow dissolving materials, and said intragranular fast dissolving carrier is completely or partially encapsulated or included or coated in said slow dissolving materials, wherein said extragranular fast dissolving carrier and said slow dissolving carrier are at a weight ratio of 0.3 to 0.5;
MODIFICATION TO “LICENSE AND SETTLEMENT AGREEMENT” OF FEBRUARY 17, 2005License and Settlement Agreement • June 30th, 2005 • Las Vegas From Home Com Entertainment Inc • Services-amusement & recreation services
This Modification is entered into this 6th day of May, 2005, by and between 1st Technology LLC (hereinafter “1st Technology”) and LasVegasFromHome.com Entertainment, Inc. (hereinafter “LVFH.com”).
LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • May 11th, 2009 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Arizona
This matter is before the Court on the unopposed motion of Plaintiff Medicis Pharmaceutical Corporation (“Medicis”) and Defendants Perrigo Israel Pharmaceuticals, Ltd. and Perrigo Company (collectively, “Perrigo”).
FOR EXECUTION ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.License and Settlement Agreement • February 29th, 2016 • Horizon Pharma PLC • Pharmaceutical preparations • Delaware
This LICENSE AND SETTLEMENT AGREEMENT (this “Agreement”), dated October 1, 2015 (the “Execution Date”), is hereby entered into by and among Horizon Pharma Switzerland GmbH (formerly known as Horizon Pharma AG), a Swiss company with its principal place of business at Kagenstrasse 17, CH-4153 Reinach, Switzerland (“Horizon Pharma Switzerland”), Jagotec AG, a Swiss company with its principal place of business at Eptingerstrasse 61, CH-4132 Muttenz, Switzerland (“Jagotec”) (Horizon Pharma Switzerland and Jagotec, individually referred to as a “Licensor” and collectively referred to as “Licensors”), and Actavis Laboratories FL, Inc. (formerly known as Watson Laboratories, Inc. – Florida), a Florida Corporation with a principal place of business at 4955 Orange Drive, Davie, Florida 33314 (“Actavis”) (each individually a “Party”, collectively, “Parties”).
LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • November 9th, 2011 • Medicis Pharmaceutical Corp • Pharmaceutical preparations • Delaware
WHEREAS Medicis and Nycomed have entered into a License and Settlement Agreement pursuant to which they have resolved the Litigations;
